egfl7 epidermal growth factor-like protein Search Results


pdgf elisa kits  (Boster Bio)
90
Boster Bio pdgf elisa kits
Figure 5. Paracrine capacity of NBM‑MSCs and DBM‑MSCs. (A) Quantification of TGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. There was no significant difference between the expression levels (P>0.05). (B) Quantification of <t>PDGF</t> concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. No significant difference was identified between them (P>0.05). TGF and PDGF concentrations were detected using enzyme‑linked immunosorbent assays. Data are presented as the mean ± standard deviation. BM‑MSCs, bone marrow‑derived mes enchymal stem cells from normal saline‑treated mice; DBM‑MSCs, bone marrow‑derived mesenchymal stem cells from dimethyloxallyl glycine‑pre conditioned mice; TGF, transforming growth factor; PDGF, platelet‑derived growth factor.
Pdgf Elisa Kits, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdgf elisa kits/product/Boster Bio
Average 90 stars, based on 1 article reviews
pdgf elisa kits - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human egfl7 kits  (Cusabio)
92
Cusabio human egfl7 kits
<t>EGFL7</t> levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.
Human Egfl7 Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human egfl7 kits/product/Cusabio
Average 92 stars, based on 1 article reviews
human egfl7 kits - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
egfl7  (Boster Bio)
90
Boster Bio egfl7
<t>EGFL7</t> levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.
Egfl7, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/egfl7/product/Boster Bio
Average 90 stars, based on 1 article reviews
egfl7 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Figure 5. Paracrine capacity of NBM‑MSCs and DBM‑MSCs. (A) Quantification of TGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. There was no significant difference between the expression levels (P>0.05). (B) Quantification of PDGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. No significant difference was identified between them (P>0.05). TGF and PDGF concentrations were detected using enzyme‑linked immunosorbent assays. Data are presented as the mean ± standard deviation. BM‑MSCs, bone marrow‑derived mes enchymal stem cells from normal saline‑treated mice; DBM‑MSCs, bone marrow‑derived mesenchymal stem cells from dimethyloxallyl glycine‑pre conditioned mice; TGF, transforming growth factor; PDGF, platelet‑derived growth factor.

Journal: Molecular medicine reports

Article Title: Characterization of bone marrow-derived mesenchymal stem cells from dimethyloxallyl glycine-preconditioned mice: Evaluation of the feasibility of dimethyloxallyl glycine as a mobilization agent.

doi: 10.3892/mmr.2016.4945

Figure Lengend Snippet: Figure 5. Paracrine capacity of NBM‑MSCs and DBM‑MSCs. (A) Quantification of TGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. There was no significant difference between the expression levels (P>0.05). (B) Quantification of PDGF concentration in the culture supernatant of NBM‑MSCs and DBM‑MSCs. No significant difference was identified between them (P>0.05). TGF and PDGF concentrations were detected using enzyme‑linked immunosorbent assays. Data are presented as the mean ± standard deviation. BM‑MSCs, bone marrow‑derived mes enchymal stem cells from normal saline‑treated mice; DBM‑MSCs, bone marrow‑derived mesenchymal stem cells from dimethyloxallyl glycine‑pre conditioned mice; TGF, transforming growth factor; PDGF, platelet‑derived growth factor.

Article Snippet: Mouse TGF (β IG-H3) and PDGF ELISA kits (Wuhan Boster Biological Co., Ltd., Wuhan, China) were used, according to the manufacturer's protocol.

Techniques: Concentration Assay, Expressing, Standard Deviation

EGFL7 levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.

Journal: Scientific Reports

Article Title: Circulating EGFL7 distinguishes between IUGR and PE: an observational case–control study

doi: 10.1038/s41598-021-97482-2

Figure Lengend Snippet: EGFL7 levels in non-pregnant women, healthy pregnant women, and pregnant women affected by IUGR, Early PE and Late PE. ( A ) Mean (± SE) levels of Epidermal Growth Factor-like Domain 7 (EGFL7) in plasma of non-pregnant women (NP), healthy pregnant women (Controls), IUGR-, Early PE- (e-PE) and Late PE- (l-PE) affected pregnant women throughout pregnancy as measured by ELISA. Data were compared using the two-sample t -test between two samples ( p < 0.001 for e-PE vs. CTRL and IUGR at GA 22–25; p = 0.05 for e-PE vs. CTRL and IUGR at GA 26–30; p = 0.045 for e-PE vs. IUGR at GA 31–34; p = 0.01 for l-PE vs. CTRL) or ANOVA test among the three studied groups ( p < 0.001 at GA 22–25 and p = 0.036 at GA 35–40). Statistically significant difference within gestational interval is reported. SigmaPlot 12.0 and GraphPad Prism 7 were used for statistical analysis. ( B ) Real-time PCR analysis for EGFL7 gene expression levels in placental samples obtained from Controls, IUGR- and l-PE- affected pregnant women at GA 35–40. Data were represented as mean (± SE). ANOVA test with post-hoc Bonferroni correction was used for statistical analysis (SigmaPlot 12.0). Differences were considered significant at p < 0.05.

Article Snippet: Human EGFL7 kits were purchased from Cusabio Biotech (College Park, Maryland, USA).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Real-time Polymerase Chain Reaction, Gene Expression